SAN DIEGO, May 22 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals,
Inc. (Nasdaq: AMLN) will be presenting at the FBR Capital Markets Investor
Conference in New York on Wednesday, May 28, 2008 at 9:45 a.m. ET / 6:45
a.m. PT. David M. Kendall, M.D., Executive Director, Medical Affairs of
Amylin Pharmaceuticals, will be providing a corporate overview.
The live presentation and breakout session will be webcast, and a
recording will be made available following the event. The webcast and
recording will be accessible through Amylin's corporate website, located at
http://www.amylin.com. To access the live webcast, please log on to
Amylin's site approximately fifteen minutes prior to the presentation to
register and download any necessary audio software.
About Amylin Pharmaceuticals
Amylin Pharmaceuticals is a biopharmaceutical company committed to
improving lives through the discovery, development and commercialization of
innovative medicines. Amylin has developed and gained approval for two
first- in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate)
injection and BYETTA(R) (exenatide) injection. Amylin's research and
development activities leverage the company's expertise in metabolism to
develop potential therapies to treat diabetes and obesity. Amylin is
headquartered in San Diego, California with over 1,900 employees
nationwide. Further information on Amylin Pharmaceuticals is available at
http://www.amylin.com.
SOURCE Amylin Pharmaceuticals, Inc.
 back to top
Related links:
http://www.amylin.com/
CONTACT:
Michael York, Senior Director, Investor
Relations of Amylin Pharmaceuticals, Inc., +1-858-552-2200 x8602
|
